IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of ...

Dr. Mizui is Founder and President of Eisai Innovations, Inc. and Former Global Business Development and Strategy Head in ...

AstraZeneca’s Phase 3 study in bladder cancer, showed that giving Imfinzi — before and after surgery — cut the risk of death.

GE HealthCare’s recently acquired MIM Software division has secured an FDA clearance for a tool to help quantify the density ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

Tony Downs was a powerhouse lawyer with an uncanny memory before the memory-robbing disease took hold. Now, he and his wife are hoping Leqembi, a newly approved drug, will help slow his decline.

JonesTrading analyst Soumit Roy reiterated a Buy rating on Acrivon Therapeutics, Inc. (ACRV – Research Report) today and set a price ...

This industry-sponsored symposium took place during the European Association of Neurology (EAN) Congress held in Helsinki, Finland, 29 June−2 July, 2024.

The drug, which was developed by US firm Biogen and Japanese firm Eisai, works by reducing amyloid plaques that ... also considering factors such as fertility and menopause in how the company ...

Dr. Mizui is Founder and President of Eisai Innovations, Inc. and Former Global Business Development and Strategy Head in Eisai’s Oncology Business Group Brings Nearly 30 Years of Experience in Drug ...

New CFO Brings Multiple Years of Experience from Biotech Companies- As Part of the New Hire, the Company Issues Inducement ...

The European Organization for Research and Treatment of Cancer (EORTC), a network of 3,800 members across 50 countries, is ...